These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer. Wang K; Yan L; Qiu X; Chen H; Gao F; Ge W; Lian Z; Wei X; Wang S; He H; Xu X Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167236. PubMed ID: 38740225 [TBL] [Abstract][Full Text] [Related]
10. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581 [TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma. Du B; Wen X; Wang Y; Lin M; Lai J Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034 [TBL] [Abstract][Full Text] [Related]
12. Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy. Gondaliya P; Sayyed AA; Yan IK; Driscoll J; Ziemer A; Patel T Mol Ther; 2024 Aug; 32(8):2762-2777. PubMed ID: 38859589 [TBL] [Abstract][Full Text] [Related]
13. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091 [TBL] [Abstract][Full Text] [Related]
14. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035 [TBL] [Abstract][Full Text] [Related]
15. Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation. Lo YL; Li CY; Chou TF; Yang CP; Wu LL; Chen CJ; Chang YH Biomed Pharmacother; 2024 Jun; 175():116660. PubMed ID: 38701563 [TBL] [Abstract][Full Text] [Related]
16. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. Li D; Schaub N; Guerin TM; Bapiro TE; Richards FM; Chen V; Talsania K; Kumar P; Gilbert DJ; Schlomer JJ; Kim SJ; Sorber R; Teper Y; Bautista W; Palena C; Ock CY; Jodrell DI; Pate N; Mehta M; Zhao Y; Kozlov S; Rudloff U Mol Cancer Ther; 2021 Oct; 20(10):1926-1940. PubMed ID: 34376576 [TBL] [Abstract][Full Text] [Related]
17. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003 [TBL] [Abstract][Full Text] [Related]
18. Anti-PD-L1 checkpoint inhibitor combined with nanocarrier-mediated cisplatin codelivery system for effective treatment of pancreatic cancer. Jia ZY; Yan X; Zhou H; Wang W; Li C; Zhang BL Mol Immunol; 2024 Oct; 174():69-76. PubMed ID: 39216237 [TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722 [TBL] [Abstract][Full Text] [Related]